A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma

Trial Profile

A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neurofibromatosis 2
  • Focus Therapeutic Use
  • Acronyms AFINF2
  • Most Recent Events

    • 22 May 2017 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
    • 29 Jan 2016 New source Identified and integrated (NCT01490476).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top